Crossject (ALCJ)

Currency in EUR
1.962
+0.024(+1.24%)
Closed·
ALCJ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.8981.998
52 wk Range
1.0602.695
Key Statistics
Prev. Close
1.938
Open
1.9
Day's Range
1.898-1.998
52 wk Range
1.06-2.695
Volume
183.3K
Average Volume (3m)
257.36K
1-Year Change
93.3005%
Book Value / Share
-0.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALCJ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.300
Upside
+119.16%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Crossject News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.300
(+119.16% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
25-03-2026
EPS / Forecast
-- / --
Revenue / Forecast
1.03M / --
EPS Revisions
Last 90 days

ALCJ Income Statement

Compare ALCJ to Peers and Sector

Metrics to compare
ALCJ
Peers
Sector
Relationship
P/E Ratio
−10.0x−1.3x−0.5x
PEG Ratio
-−0.160.00
Price/Book
−21.2x1.7x2.6x
Price / LTM Sales
40.3x0.9x3.2x
Upside (Analyst Target)
119.2%29.8%47.8%
Fair Value Upside
Unlock28.4%5.9%Unlock

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.

Employees
103
Market
France

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
488.26K0.93%932.57K
Other Institutional Investors
0.000.00%0.00
Public Companies & Retail Investors
52.25M99.07%99.80M
Total
52.74M100.00%100.73M

FAQ

What Is the Crossject (ALCJ) Share Price Today?

The Crossject share price today is 1.962.

What is the current Crossject (ALCJ) share price and day range?

As of 06-05-2026, the Crossject share price is 1.962, with a previous close of 1.938. The share price has ranged from 1.898 to 1.998 today, while the 52-week range spans from 1.060 to 2.695.

What Is the Crossject Market Cap?

As of today, Crossject market cap is 103.900M.

What Is the Crossject (ALCJ) Share Price Target?

The average 12-month share price target for Crossject is 4.300, with a high estimate of 4.5 and a low estimate of 4.1. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +119.16% Upside potential.

From a Technical Analysis Perspective, Is ALCJ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

What Stock Exchange Does Crossject Trade On?

Crossject is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Crossject?

The stock symbol for Crossject is "ALCJ."

How Many Times Has Crossject Stock Split?

Crossject has split 2 times.

How Many Employees Does Crossject Have?

Crossject has 103 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.